These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24721645)

  • 21. Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma.
    Krajsová I; Arenberger P; Lakomý R; Kubala E; Březinová I; Poprach A; Šťastný M; Mužík J; Melichar B
    Anticancer Res; 2015 Nov; 35(11):6303-10. PubMed ID: 26504067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.
    Wistuba-Hamprecht K; Martens A; Haehnel K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Demuth I; Steinhagen-Thiessen E; Larbi A; Schilling B; Schadendorf D; Wolchok JD; Blank CU; Pawelec G; Garbe C; Weide B
    Eur J Cancer; 2016 Sep; 64():116-26. PubMed ID: 27400322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of tyrosinase mRNA detected by nested RT-PCR in patients with malignant melanoma.
    Glumac N; Snoj M; Hocevar M; Novakovic S
    Neoplasma; 2006; 53(1):9-14. PubMed ID: 16416006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
    Ribas A; Hanson DC; Noe DA; Millham R; Guyot DJ; Bernstein SH; Canniff PC; Sharma A; Gomez-Navarro J
    Oncologist; 2007 Jul; 12(7):873-83. PubMed ID: 17673618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical development of the anti-CTLA-4 antibody tremelimumab.
    Ribas A
    Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.
    Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Kuo C; Wang HJ; Milford R; Morton DL; Hoon DS
    Clin Cancer Res; 2006 Feb; 12(4):1137-43. PubMed ID: 16489066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis.
    van Gils W; Lodder EM; Mensink HW; Kiliç E; Naus NC; Brüggenwirth HT; van Ijcken W; Paridaens D; Luyten GP; de Klein A
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4254-62. PubMed ID: 18552379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of differential display to identify genes for lung cancer detection in peripheral blood.
    Matsunaga H; Hangai N; Aso Y; Okano K; Kawamura M; Kobayashi K; Kambara H; Hoger JH; Mitsuhashi M
    Int J Cancer; 2002 Aug; 100(5):592-9. PubMed ID: 12124810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
    Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
    Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma.
    Ghossein RA; Coit D; Brennan M; Zhang ZF; Wang Y; Bhattacharya S; Houghton A; Rosai J
    Clin Cancer Res; 1998 Feb; 4(2):419-28. PubMed ID: 9516931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Morphomics predicts response to ipilimumab in patients with stage IV melanoma.
    Sabel MS; Lee J; Wang A; Lao C; Holcombe S; Wang S
    J Surg Oncol; 2015 Sep; 112(4):333-7. PubMed ID: 26251199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma.
    Schuster R; Bechrakis NE; Stroux A; Busse A; Schmittel A; Scheibenbogen C; Thiel E; Foerster MH; Keilholz U
    Clin Cancer Res; 2007 Feb; 13(4):1171-8. PubMed ID: 17317826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum S100B levels correlate with clinical benefit in a metastatic melanoma patient treated by CTLA-4 blockade: a case report.
    Loquai C; Müller-Brenne T; Schadmand-Fischer S; Grabbe S
    Onkologie; 2013; 36(10):578-81. PubMed ID: 24107912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
    Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
    J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CTLA4 blockade broadens the peripheral T-cell receptor repertoire.
    Robert L; Tsoi J; Wang X; Emerson R; Homet B; Chodon T; Mok S; Huang RR; Cochran AJ; Comin-Anduix B; Koya RC; Graeber TG; Robins H; Ribas A
    Clin Cancer Res; 2014 May; 20(9):2424-32. PubMed ID: 24583799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence.
    Marques AR; Teixeira E; Diamond J; Correia H; Santos S; Neto L; Ribeiro M; Miranda A; Passos-Coelho JL
    Breast Cancer Res Treat; 2009 Mar; 114(2):223-32. PubMed ID: 18409061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
    Comin-Anduix B; Lee Y; Jalil J; Algazi A; de la Rocha P; Camacho LH; Bozon VA; Bulanhagui CA; Seja E; Villanueva A; Straatsma BR; Gualberto A; Economou JS; Glaspy JA; Gomez-Navarro J; Ribas A
    J Transl Med; 2008 May; 6():22. PubMed ID: 18452610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.
    Bozionellou V; Mavroudis D; Perraki M; Papadopoulos S; Apostolaki S; Stathopoulos E; Stathopoulou A; Lianidou E; Georgoulias V
    Clin Cancer Res; 2004 Dec; 10(24):8185-94. PubMed ID: 15623593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.